从蛋白酶抑制剂方案转换为多替拉韦方案对HIV储存库的影响:一项随机临床试验
INDOOR试验为4期开放标签随机临床试验,纳入42例接受有效cART的HIV-1感染者,比较转换为多替拉韦(DTG)方案与继续蛋白酶抑制剂(PI/r)方案对外周血和回肠活检中HIV储存库的影响。
要点
- 转换为DTG方案安全耐受,无相关不良事件或停药。
- 回肠HIV储存库持续大于外周血,转换未显著改变储存库标志物。
核心结论
- 从PI/r方案转换为DTG方案安全且耐受良好,但对外周血和回肠CD4+ T细胞中HIV储存库标志物及免疫炎症标志物无显著影响。
研究设计与样本
- INDOOR为4期开放标签随机临床试验,纳入42例接受有效cART的HIV-1感染者,随机分为转换组(20例,从PI/r转换为DTG)和对照组(22例,继续PI/r方案)。
主要发现
- 未观察到低水平病毒复制、总HIV DNA和整合HIV DNA、HIV转录、T细胞成熟亚群、免疫激活标志物、炎症可溶性蛋白或潜伏感染细胞标志物的显著纵向变化。
临床怎么用
- 对于病毒学抑制的HIV感染者,从PI/r方案转换为DTG方案是安全可行的,但不应预期该转换能显著缩小HIV储存库或改善免疫炎症指标。
局限性
- 样本量较小(共42例),随访时间未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimization of combination antiretroviral therapy (cART) can impact the human immunodeficiency virus (HIV) reservoir. We evaluated the effect on the HIV reservoir in peripheral blood and ileum biopsies in patients switching from boosted protease inhibitor (PI/r)-based therapy to dolutegravir (DTG)-based therapy. METHODS: Impact of Integrase-inhibitor DOlutegravir On the viral Reservoir (INDOOR) is a phase 4 open-label clinical trial that randomly included 42 HIV type 1-infected individuals on effective cART: 20 who switched from PI/r-based to DTG-based cART (switch group), and 22 who remained in PI/r-based regimens (control group). We analyzed blood and ileum biopsies to quantify episomal, total, and integrated HIV DNA, cell-associated HIV RNA, residual plasma viremia, T-cell subsets, cell activation, and inflammation markers. RESULTS: There were no related adverse events or treatment discontinuations due to drug intolerance. The HIV reservoir was consistently larger in ileal than in peripheral CD4+ T cells in both groups (P < .01). Residual viremia in plasma decreased in the switch group (P = .03). However, we did not observe significant longitudinal changes in low-level viral replication, total and integrated HIV reservoir, HIV transcription, T-cell maturation subsets, immunoactivation markers, inflammatory soluble proteins, or cellular markers of latently infected cells. CONCLUSIONS: The INDOOR study is the first evaluation of changes in HIV reservoir size in ileum biopsies and in peripheral blood in individuals switched from PI/r- to DTG-based cART. Although this switch was safe and well tolerated, it had no impact on a large array of immunological and inflammatory markers or on HIV reservoir markers in peripheral or in ileal CD4+ T cells. CLINICAL TRIALS REGISTRATION: EudraCT 2014-004331-39.
引用
- Morón-López S, Navarro J, Jimenez M, et al. Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals. Clin Infect Dis. 2019. PMID: 30590412. doi:10.1093/cid/ciy1095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。